Publication: Evolution of coreceptor utilization to escape CCR5 antagonist therapy
Open/View Files
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Zhang, Jie, Xiang Gao, John Martin, Bruce Rosa, Zheng Chen, Makedonka Mitreva, Timothy Henrich, Daniel Kuritzkes, and Lee Ratner. 2016. “Evolution of coreceptor utilization to escape CCR5 antagonist therapy.” Virology 494 (1): 198-214. doi:10.1016/j.virol.2016.04.010. http://dx.doi.org/10.1016/j.virol.2016.04.010.
Research Data
Abstract
The HIV-1 envelope interacts with coreceptors CCR5 and CXCR4 in a dynamic, multi-step process, its molecular details not clearly delineated. Use of CCR5 antagonists results in tropism shift and therapeutic failure. Here we describe a novel approach using full-length patient-derived gp160 quasispecies libraries cloned into HIV-1 molecular clones, their separation based on phenotypic tropism in vitro, and deep sequencing of the resultant variants for structure-function analyses. Analysis of functionally validated envelope sequences from patients who failed CCR5 antagonist therapy revealed determinants strongly associated with coreceptor specificity, especially at the gp120-gp41 and gp41-gp41 interaction surfaces that invite future research on the roles of subunit interaction and envelope trimer stability in coreceptor usage. This study identifies important structure-function relationships in HIV-1 envelope, and demonstrates proof of concept for a new integrated analysis method that facilitates laboratory discovery of resistant mutants to aid in development of other therapeutic agents.
Description
Other Available Sources
Keywords
HIV/AIDS, Tropism shift, Coreceptor inhibitor, Drug resistance
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service